Stay updated with breaking news from Marka Mcpartland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on trackPALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stag...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 27, 2023--
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 27, 2023--
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen’s Chief Executive Officer, will participate in the following investor conferences in March: Maxim Group and M-Vest’s Inaugural Emergi...